Related Experiment Video
Updated: Jul 15, 2026
10:15
Isolation and Culture Expansion of Tumor-specific Endothelial Cells
Published on: October 14, 2015
Tumor-endothelial cell interactions: therapeutic potential.
Megumi Iiizumi1, Sonia Mohinta, Sucharita Bandyopadhyay
1Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, 801 N. Rutledge St., P.O. Box 19626, Springfield, IL 62794-9626, USA.
Microvascular Research
|May 15, 2007
Summary
The KAI1 gene suppresses cancer metastasis by enabling tumor cells to bind to the Duffy antigen receptor for chemokines (DARC) on endothelial cells. This interaction induces tumor cell senescence, offering a novel therapeutic target for inhibiting metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Metastasis, the spread of cancer, is the leading cause of cancer-related death.
- The molecular mechanisms of metastasis, particularly cancer cell adhesion to endothelium, are complex and not fully understood.
- The KAI1 gene is a known suppressor of cancer metastasis.
Purpose of the Study:
- To investigate the molecular mechanisms by which KAI1 suppresses metastasis.
- To explore the interaction between KAI1 and endothelial cells in the context of metastasis.
- To identify potential therapeutic strategies for inhibiting cancer metastasis.
Main Methods:
- The study focused on the interaction between the KAI1 protein and the Duffy antigen receptor for chemokines (DARC) on endothelial cells.
- Investigated the role of this interaction in the metastatic process.
Main Results:
- KAI1 binds to DARC, a chemokine receptor expressed on endothelial cells.
- This KAI1-DARC interaction significantly induces senescence in tumor cells.
- This interaction acts as a host defense mechanism hindering metastasis.
Conclusions:
- The interaction between KAI1 and DARC on endothelial cells is a critical mechanism for suppressing cancer metastasis.
- Inducing tumor cell senescence via KAI1-DARC binding presents a novel therapeutic avenue for anti-metastasis drug development.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...